Site search2018
- 2018.12.19NewsUniversity of Tokyo and BrightPath Conclude Collaborative Research Agreement for Fully Personalized Cancer Immunotherapy（167KB）
- 2018.11.9IRFinancial Results for the Second Quarter of the Fiscal Year Ending March 31, 2019 [Japanese GAAP] (Consolidated)（162 KB）
- 2018.10.12IRAnnouncement on Dissolution of a Subsidiary（324KB）
- 2018.10.12IRAnnouncement on Resignation of a Director（341KB）
- 2018.8.10IRAnnouncement of Recognition of Extraordinary Loss (Impairment Loss)（272KB）
- 2018.8.10IRFinancial Results for the First Quarter of the Fiscal Year Ending March 31, 2019 [Japanese GAAP] (Consolidated)（143KB）
- 2018.5.17IRAnnouncement on the Results of the Phase III Clinical Trial for Cancer Peptide Vaccine ITK-1 in Patients in Japan with Prostate Cancer（276KB）
- 2018.5.11IRAnnouncement of Candidate for Director（128KB）
- 2018.5.11IRFinancial Results for the Fiscal Year ended March 31, 2018 [Japanese GAAP] (Consolidated)（505KB）
- 2018.3.29IRCollaborative research agreement concluded with RIKEN on iPS cell-derived NKT cell therapy（801KB）
- 2018.2.15NewsMie University and BrightPath Launch New Program for Neoantigen-based Personalized Cancer Immunotherapy（187KB）
- 2018.2.14IRFinancial Results for the Third Quarter of the Fiscal Year Ending March 31, 2018 [Japanese GAAP] (Consolidated)（395KB）
- 2018.1.25NewsBrightPath concludes agreement to develop personalized cancer vaccine（322KB）
- 2018.11.9IRFinancial Results for the Second Quarter of the Fiscal Year Ending March 31, 2019 [Japanese GAAP] (Consolidated)（162 KB）
- 2018.10.12IRAnnouncement on Dissolution of a Subsidiary（324KB）
- 2018.10.12IRAnnouncement on Resignation of a Director（341KB）
- 2018.8.10IRAnnouncement of Recognition of Extraordinary Loss (Impairment Loss)（272KB）
- 2018.8.10IRFinancial Results for the First Quarter of the Fiscal Year Ending March 31, 2019 [Japanese GAAP] (Consolidated)（143KB）
- 2018.5.17IRAnnouncement on the Results of the Phase III Clinical Trial for Cancer Peptide Vaccine ITK-1 in Patients in Japan with Prostate Cancer（276KB）
- 2018.5.11IRAnnouncement of Candidate for Director（128KB）
- 2018.5.11IRFinancial Results for the Fiscal Year ended March 31, 2018 [Japanese GAAP] (Consolidated)（505KB）
- 2018.3.29IRCollaborative research agreement concluded with RIKEN on iPS cell-derived NKT cell therapy（801KB）
- 2018.2.14IRFinancial Results for the Third Quarter of the Fiscal Year Ending March 31, 2018 [Japanese GAAP] (Consolidated)（395KB）
- 2018.12.19NewsUniversity of Tokyo and BrightPath Conclude Collaborative Research Agreement for Fully Personalized Cancer Immunotherapy（167KB）
- 2018.2.15NewsMie University and BrightPath Launch New Program for Neoantigen-based Personalized Cancer Immunotherapy（187KB）
- 2018.1.25NewsBrightPath concludes agreement to develop personalized cancer vaccine（322KB）